Measurement method for fibroblast growth factor-23 by forming immunocomplexes
A method for measuring fibroblast growth factor-23 (hereinafter, indicated as FGF-23) in a sample, which comprises the steps of: (1) reacting in an aqueous medium, a sample and a first antibody or an antibody fragment thereof which binds to FGF-23; (2) reacting in an aqueous medium, a second antibody or an antibody fragment thereof which binds to FGF-23 with Immunocomplex 1 produced in the aforementioned step (1) to produce Immunocomplex 2 consisting of the first antibody or the antibody fragment thereof which binds to FGF-23, FGF-23, and the second antibody or the antibody fragment thereof which binds to FGF-23; and (3) measuring Immunocomplex 2 produced in the aforementioned step (2); wherein the reaction of step (1) and/or step (2) is carried out in an aqueous medium comprising a surfactant such as a polyoxyethylene alkyl ether.
1 . A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprises the steps of:
(1) reacting in a first aqueous medium, a sample and a first antibody produced by FERM BP-7838 hybridoma or an antibody fragment thereof which binds to FGF-23 to produce Immunocomplex 1 consisting of FGF-23 and the first antibody or the antibody fragment thereof which binds to FGF-23;
(2) reacting in a second aqueous medium, a second antibody produced by FERM BP-7839 hybridoma or an antibody fragment thereof which binds to FGF-23 with Immunocomplex 1 produced in the aforementioned step (1) to produce Immunocomplex 2 consisting of the first antibody or the antibody fragment thereof which binds to FGF-23, FGF-23, and the second antibody or the antibody fragment thereof which binds to FGF-23; and
(3) measuring Immunocomplex 2 produced in the aforementioned step (2);
wherein
the first aqueous medium comprises at least one type of surfactant selected from the group consisting of NONION E-230, NONION K-220, PLONON 208, and NEWCOL 740, or
the first aqueous medium comprises at least one type of surfactant selected from the group consisting of NONION E-230, NONION K-220, PLONON 208, and NEWCOL 740 and the second aqueous medium is the same as first aqueous medium.
2 . The method of claim 1 , where in the second antibody or the antibody fragment thereof which binds to FGF-23 comprises a Fab′ fragment of FERM BP-7839 monoclonal antibody labeled with an alkaline phosphatase.
3 . The method of claim 1 , wherein the reaction of step (1) is carried out in the first aqueous medium comprising at least one type of surfactant selected from the group consisting of NONION E-230, NONION K-220, PLONON 208, and NEWCOL 740, using an insoluble carrier to produce the Immunocomplex 1 on the insoluble carrier, and wherein the insoluble carrier is washed after step (1) and before step (2).
4 . The method of claim 1 , wherein the second aqueous medium is the same as the first aqueous medium.
5 . The method of claim 1 , wherein the surfactant comprises NONION E-230.
6 . The method of claim 1 , wherein the surfactant comprises NONION K-220.
7 . The method of claim 1 , wherein the surfactant comprises PLONON 208.
8 . The method of claim 1 , wherein the surfactant comprises Newcol 740.
9 . The method of claim 1 , wherein the second antibody is labeled with one or more selected from an enzyme, a fluorescent substance, a luminescent substance, a radioisotope, biotin, digoxigenin, a polypeptide containing a tag sequence, a metallic colloid particle, and a colored latex particle.
10 . The method of claim 9 , wherein the enzyme comprises alkaline phosphatase, peroxidase, galactosidase, glucuronidase, or luciferase.
11 . The method of claim 9 , wherein the fluorescent substance comprises one or more selected from the group consisting of fluorescein isothiocyanate (FITC), rhodamine B-isothiocyanate (RITC), quantum dot (Science, 281, 2016-2018, 1998), phycobiliproteins, and fluorescence-emitting proteins.
12 . The method of claim 9 , wherein the luminescent substance comprises one or more selected from the group consisting of acridinium ester and derivatives thereof, a ruthenium complex compound, and lophine.
13 . The method of claim 9 , wherein the radioisotope comprises one or more selected from the group consisting of 3 H, 14 C, 35 S, 32 P, 125 I, and 131 I.